


Data Sheet

Product Name:	SM-164 (hydrochloride)
Cat. No.:	CS-0041048
CAS No.:	2734174-02-6
Molecular Formula:	C ₆₂ H ₈₅ ClN ₁₄ O ₆
Molecular Weight:	1157.88
Target:	Apoptosis; IAP
Pathway:	Apoptosis
Solubility:	H ₂ O : ≥ 106 mg/mL



BIOLOGICAL ACTIVITY:

SM-164 hydrochloride is a cell-permeable Smac mimetic compound. SM-164 binds to **XIAP** protein containing both the BIR2 and BIR3 domains with an **IC₅₀** value of 1.39 nM and functions as an extremely potent antagonist of **XIAP**. IC₅₀ & Target:IC₅₀: 1.39 nM (XIAP)^[1]

K_i: 0.56 nM to (XIAP), 0.31 nM to (cIAP-1), 1.1 nM (cIAP-2)^[2] *In Vitro*: SM-164 is a non-peptide, cell-permeable, bivalent small-molecule, which mimics Smac protein for targeting XIAP. SM-164 binds to XIAP containing both BIR domains with an IC₅₀ value of 1.39 nM, being 300 and 7000-times more potent than its monovalent counterparts and the natural Smac AVPI peptide, respectively. SM-164 concurrently interacts with both BIR domains in XIAP and functions as an ultra-potent antagonist of XIAP in both cell-free functional and cell-based assays. SM-164 targets cellular XIAP and effectively induces apoptosis at concentrations as low as 1 nM in leukemia cancer cells, while having a minimal toxicity to normal human primary cells at 10,000 nM^[1]. The binding affinities of SM-164 to XIAP, cIAP-1, and cIAP-2 proteins are determined using fluorescence-polarization based assays. SM-164 has a K_i value of 0.56 nM to XIAP protein containing both BIR2 and BIR3 domains. SM-164 has a K_i value of 0.31 nM to cIAP-1 protein containing both BIR2 and BIR3 domains. SM-164 binds to cIAP-2 BIR3 protein with K_i values of 1.1 nM. Addition of exogenous TNFα can significantly enhance the activity of these Smac mimetics, especially for SM-164, in resistant cancer cell lines such as HCT116 and MDA-MB-453^[2]. *In Vivo*: SM-164 is evaluated for its ability to inhibit tumor growth. SM-164 is highly effective in inhibition of tumor growth and capable of achieving tumor regression in the MDA-MB-231 xenograft model. Treatment with SM-164 at 1 mg/kg completely inhibits tumor growth during the treatment. Treatment with SM-164 at 5 mg/kg reduces the tumor volume from 147±54 mm³ at the beginning of the treatment (day 25) to 54±32 mm³ at the end of the treatment (day 36), a reduction of 65%. The strong antitumor activity by SM-164 is long lasting and not transient. SM-164 at 5 mg/kg is statistically more effective than Taxotere at the end of the treatment (P<0.01) or when the tumor size in the control group reaches 750 mm³ (P<0.02)^[2].

PROTOCOL (Extracted from published papers and Only for reference)

Kinase Assay: ^[2]A set of sensitive and quantitative fluorescence polarization (FP)-based assays are developed to determine the binding affinities of our designed Smac mimetics to XIAP BIR3, XIAP containing both BIR2 and BIR3 domains, cIAP-1 BIR3, cIAP-1 containing both BIR2 and BIR3 domains, and cIAP-2 protein. The FP-based assay for XIAP BIR3 protein is measured. Briefly, 5-carboxyfluorescein is coupled to the lysine side chain of a mutated Smac peptide with the sequence (AbuRPFK-Fam) and this fluorescently tagged peptide (named SM5F) is used as the fluorescent tracer in FP-based binding assay to XIAP BIR3. The K_d value of this fluorescent tracer is determined to be 17.9 nM to XIAP BIR3. In competitive binding experiments, a tested compound is incubated with 30 nM of XIAP BIR3 protein and 5 nM of SM5F in the assay buffer (100 mM potassium phosphate, pH 7.5; 100µg/mL bovine gamma globulin; 0.02 % sodium azide)^[2].

Cell Assay: ^[2]**HCT116 colon cancer cells** are treated with **SM-164 (1, 10, and 100 nM)** alone, TNF α alone, or the combination for 48 h. Cell growth inhibition is determined by a WST assay^[2].

Animal Administration: ^[2]Mice^[2]

SCID mice (8-10 per group) bearing MDA-MB-231 xenograft tumors are treated **i.v. with 1 and 5 mg/kg of SM-164** or 7.5 mg/kg of Taxotere or vehicle control daily, 5 d/wk for 2 wk. Tumor sizes and animal weights are measured thrice a week^[2].

References:

[1]. Sun H, et al. Design, synthesis, and characterization of a potent, nonpeptide, cell-permeable, bivalent Smac mimetic that concurrently targets both the BIR2 and BIR3 domains in XIAP. J Am Chem Soc. 2007 Dec 12;129(49):15279-94.

[2]. Lu J, et al. SM-164: a novel, bivalent Smac mimetic that induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP-1/2 and XIAP. Cancer Res. 2008 Nov 15;68(22):9384-93.

CAIndexNames:

Pyrrolo[1,2-a]azocine-3-carboxamide, N,N'-[1,4-phenylenebis[4,1-butanediyl-1H-1,2,3-triazole-1,4-diyl[(S)-phenylmethylene]]]bis[decahydro-6-[[[(2S)-2-(methylamino)-1-oxopropyl]amino]-5-oxo-, (3S,3'S,6S,6'S,10aS,10'aS)-],hydrochloride

SMILES:

C[C@H](NC)C(N[C@H]1CCCC[C@](CC[C@H]2C(N[C@@H](C3=CC=CC=C3)C4=CN(CCCCC5=CC=C(CCCCN6N=NC([C@@H](NC([C@@H]7CC[C@@]([CCCC[C@@H]8NC([C@@H](NC)C=O)([H])N7C8=O)=O)C9=CC=CC=C9)=C6)C=C5)N=N4)=O)([H])N2C1=O)=O.Cl

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 610-426-3128

Fax: 888-484-5008

E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr, Suite F, Monmouth Junction, NJ 08852, USA